IMPACT Therapeutics, Inc
Research IMPACT Therapeutics, Inc (7630.HK) on Bullrun: market cap HKD 3.68B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7630.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyHKD
- Market capHKD 3.68B
- Financial periodFY2025
- RevenueCNY 38.25M
- Revenue growth14.0%
- Net income-CNY 295.92M
- Free cash flow-CNY 97.39M
- Gross margin95.9%
Valuation Snapshot
latest market cap is HKD 3.68B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 38.25M | -CNY 295.92M | -CNY 97.39M | 95.9% | -1.07 | CNY 258.54M | CNY 5.44M | -CNY 957.89M |
| FY2024 | CNY 33.55M | -CNY 254.76M | -CNY 83.01M | 95.4% | -0.92 | CNY 230.12M | CNY 6.79M | -CNY 744.29M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 3.68B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About IMPACT Therapeutics, Inc
IMPACT Therapeutics, Inc., a biotechnology company, researches and develops synthetic lethality (SL)-based precision anti-cancer therapies in China and internationally. The company offers a product, (IMP4297) Senaparib, a PARP1/2 inhibitor that is used for 1L maintenance therapy for ovarian cancer (OC).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is IMPACT Therapeutics, Inc's market cap?
IMPACT Therapeutics, Inc's market capitalization is HKD 3.68B.
What does IMPACT Therapeutics, Inc do?
IMPACT Therapeutics, Inc., a biotechnology company, researches and develops synthetic lethality (SL)-based precision anti-cancer therapies in China and internationally. The company offers a product, (IMP4297) Senaparib, a PARP1/2 inhibitor that is used for 1L maintenance therapy for ovarian cancer (OC).